Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 25, 2009

View Archived Issues

Recombinant T-cell receptor ligand RTL-551 reduces stroke lesion size in vivo

Unique androgen receptor antagonists identified at Duke University Medical Center

Phase I/II studies show low systemic absorption of dapivirine vaginal gel

Novartis has disclosed novel ALK inhibitors for obstructive airways diseases

TRPA1 antagonists claimed as analgesics by Abbott

Exelixis reports creation of protein kinase inhibitors as anticancer agents

Monoamine oxidase inhibitors developed as antibacterials at Ferrer

GSK describes novel mGlu5 receptor antagonists for substance abuse

Novel hypoxia-inducible factor inhibitors reported by FibroGen

Novo Nordisk presents results for second quarter 2009

New Levitra formulation submitted for registration in E.U.

Resolvyx presents data from phase II trial of RX-10045 in dry eye syndrome

Intercept Blood System for platelets receives Swiss approval

Liverpool School of Tropical Medicine leads antimalarial drug research project

Bavarian Nordic enters negotiations with U.S. authorities for Imvamune

MF-482 developed as a second-generation EP4 antagonist for treating inflammatory pain

Takeda describes preclinical profile of GnRH antagonist TAK-385

Abbott presents PAMs that target the alpha7 nicotinic acetylcholine receptor

Seattle Genetics completes enrollment in pivitol brentuximab vedotin trial

Three phase II studies of H1N1 influenza vaccine CSL-425 planned or under way

Santaris forms strategic alliance with Shire to develop RNA-based medicines

Valeant reports preliminary results of phase IIa retigabine study in PHN

Xyzal approved for use in young children

Ligand to acquire Neurogen

BioCancell's ovarian cancer drug granted orphan drug status in U.S.

Gloucester to meet with FDA Advisory Committee to discuss romidepsin NDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...